Are Esperion Therapeutics Inc. (NASDAQ:ESPR) shares too expensive at this price?

In the latest session, Esperion Therapeutics Inc. (NASDAQ: ESPR) closed at $6.72 up 0.45% from its previous closing price of $6.69. In other words, the price has increased by $+0.03 from its previous closing price. On the day, 651095 shares were traded. ESPR stock price reached its highest trading level at $7.04 during the session, while it also had its lowest trading level at $6.64.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Ratios:

For a deeper understanding of Esperion Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 3.20.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Credit Suisse on August 03, 2022, Downgraded its rating to Underperform and sets its target price to $6 from $7 previously.

On May 05, 2022, JP Morgan Upgraded its rating to Neutral which previously was Underweight but kept the price unchanged to $6.

On March 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $22.H.C. Wainwright initiated its Buy rating on March 10, 2022, with a $22 target price.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 18 when Looker Benjamin sold 6,347 shares for $7.00 per share. The transaction valued at 44,404 led to the insider holds 64,453 shares of the business.

Foody Joanne M. sold 1,191 shares of ESPR for $8,319 on Jan 18. The Chief Medical Officer now owns 106,944 shares after completing the transaction at $6.99 per share. On Oct 18, another insider, Foody Joanne M., who serves as the Chief Medical Officer of the company, sold 942 shares for $7.69 each. As a result, the insider received 7,242 and left with 108,135 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 6.89.

Stock Price History:

Over the past 52 weeks, ESPR has reached a high of $8.87, while it has fallen to a 52-week low of $3.28. The 50-Day Moving Average of the stock is 6.65, while the 200-Day Moving Average is calculated to be 6.60.

Shares Statistics:

For the past three months, ESPR has traded an average of 1.93M shares per day and 1.66M over the past ten days. A total of 73.68M shares are outstanding, with a floating share count of 73.11M. Insiders hold about 0.60% of the company’s shares, while institutions hold 87.80% stake in the company. Shares short for ESPR as of Oct 13, 2022 were 13.33M with a Short Ratio of 16.10M, compared to 12.61M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 20.03% and a Short% of Float of 24.76%.

Earnings Estimates

There are 10 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.92 for the current quarter, with a high estimate of -$0.86 and a low estimate of -$0.98, while EPS last year was -$2.62. The consensus estimate for the next quarter is -$0.88, with high estimates of -$0.81 and low estimates of -$0.97.

Analysts are recommending an EPS of between -$3.66 and -$3.93 for the fiscal current year, implying an average EPS of -$3.8. EPS for the following year is -$2.31, with 10 analysts recommending between -$0.16 and -$3.85.

Revenue Estimates

A total of 10 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $83.96M, while the lowest revenue estimate was $70.16M, resulting in an average revenue estimate of $78.66M. In the same quarter a year ago, actual revenue was $78.45M, up 0.30% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $162M in the next fiscal year. The high estimate is $274.16M and the low estimate is $91.3M. The average revenue growth estimate for next year is up 105.90% from the average revenue estimate for this year.